Exactly even if they don't get the share price organically, they may have to implement the reverse split. That won't be a bad thing though because getting on the NASDAQ or NYSE means institutions can start to buy shares.
CYDY is in a unique place because most other OTC biotechs that I have seen uplist are only in the phase 2 stage of clinical testing. CYDY already has two phase 3 trial it will run.
Market Data 
Markets 
AI
